Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

204 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-22

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

NCT04797247

Cardiovascular Diseases Hyper-LDL-cholesterolemia

ACTIVE_NOT_RECRUITING PHASE3

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430

Cardiovascular Disease With Mention of Arteriosclerosis Elevated Cholesterol Familial Hypercholesterolemia

ENROLLING_BY_INVITATION PHASE3

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

NCT05004675

Hypercholesterolemia Atherosclerotic Ischemic Disease

COMPLETED PHASE3

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT04034485

Homozygous Familial Hypercholesterolemia

COMPLETED PHASE3

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

NCT03847974

Hypercholesterolemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, open-label Phase 3 study of 12 weeks duration comparing Q4W SC doses of LIB003 300 mg, evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg. Approximately 220 males and females aged ≥18 years who fulfill all of the inclusion and exclusion criteria will be enrolled at up to 25 sites in the United States. Patients will be stratified by baseline LDL-C and randomized in a 2:2:1 ratio to LIB003 (88 patients), Repatha (88 patients) or Praluent (44 patients) administered SC Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The total study duration will be up to 21 weeks which includes up to 9-week Screening Period (depending on period required for washout of PCSK9 mAb and/or intensification of statin treatment) and 12 weeks of study drug treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized, open-label with blinded lipid levels

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

lipid levels measured and central laboratory will be blinded to participants, investigators, and sponsor, DSMB and CEC (Cardiovascular Events Committee)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LIB003 (lerodalcibep)

300 mg SC Q4W

Group Type EXPERIMENTAL

lerodalcibep

Intervention Type BIOLOGICAL

anti-PCSK9 small binding protein

evolocumab

420 mg SC Q4W

Group Type ACTIVE_COMPARATOR

evolocumab

Intervention Type BIOLOGICAL

monoclonal antibody to PCSK9

alirocumab

300 mg SC Q4W

Group Type ACTIVE_COMPARATOR

alirocumab

Intervention Type BIOLOGICAL

monoclonal antibody to PCSK9

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lerodalcibep

anti-PCSK9 small binding protein

Intervention Type BIOLOGICAL

evolocumab

monoclonal antibody to PCSK9

Intervention Type BIOLOGICAL

alirocumab

monoclonal antibody to PCSK9

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LIB003 Repatha Praluent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* signed informed consent
* diagnosed with CVD or a high risk of CVD based on 2019 ESC/EAS guidelines
* Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥17 and ≤42 kg/m2
* LDL-C ≥90 mg/dL and TG ≤400 mg/dL while on stable diet \& lipid-lowering oral drug therapy (ie, high intensity statin with or without ezetimibe) and no PCSK9 mAb for 4 weeks if previously on Q2W dosing or 8 weeks if on Q4W dosing.
* Females of childbearing potential must be using a highly effective form of birth control if sexually active and have a negative urine pregnancy test at the last Screening Visit

Exclusion Criteria

* at screening visit: not on high intensity statin; mipomersen or lomitapide within 6 months; gemfibrozil within 6 weeks; bempedoic acid within 4 weeks; inclisiran within 12 months; apheresis within 8 weeks
* HoFH defined clinically and/or genetically
* History of prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator
* estimated glomerular filtration rate \<30 mL/min/1.73m2 at screening
* Active liver disease or hepatic dysfunction, history of liver transplant, and/or AST or ALT \>2.5 × the ULN
* Uncontrolled Type 1 or Type 2 diabetes mellitus, defined as fasting glucose ≥200 mg/dL or glycated hemoglobin (HbA1c) of ≥9%
* NY Heart Association class III-IV heart failure; or patients with last documented left ventricular ejection fraction \<30%; planned PCI, CABG or cardiac surgery
* Uncontrolled hypertension defined as evidenced by a reproducible (repeated 5 minutes apart) sitting blood pressure ≥160 mmHg systolic or ≥100 mmHg diastolic;
* Enrolled in another investigational device or drug study, or less than 30 days or 5 half-lives since ending another investigational device or drug study(ies), or receiving PCSK9 or Lp(a) siRNA or locked nucleic acid-reducing agents within 12 months of the Screening Visit;
* Have any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No